(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

We have been treating patients with positive pelvic nodes with extended-field intensity-modulated radiation therapy (IMRT) to address the PA region prophylactically with a concomitant boost to the involved nodes. The purpose of this study is to assess regional control rates and recurrence patterns with this technique.

Sushil Beriwal, Serah Choi, Hayeon Kim, Joseph L. Kelley, Robert P. Edwards, Paniti Sukumvanich, John Comerci, Alexander B. Olawaiye; University of Pittsburgh Cancer Institute

Purpose: Positron emission tomography-computed tomography (PET-CT) is commonly used for nodal staging for locally advanced cervical cancer treated with primary chemoradiation therapy. Although it has high sensitivity and specificity for pelvic nodal staging, the false negative rates for para-aortic (PA) disease is 20% to 25% in patients with PET-positive pelvic nodal disease. Unless surgical staging is done in this subset to exclude PA nodal disease, pelvis-only treatment may undertreat PA disease. We have been treating patients with positive pelvic nodes with extended-field intensity-modulated radiation therapy (IMRT) to address the PA region prophylactically with a concomitant boost to the involved nodes. The purpose of this study is to assess regional control rates and recurrence patterns with this technique.

Materials and Methods: Sixty-one patients who were diagnosed from 2003–2012 with cervical cancer of stage IB1 to IVA with PET-avid pelvic nodes that were treated with extended-field IMRT were retrospectively analyzed. The nodal location was pelvic only in 41 (67%) patients and pelvis plus the PA region in 20 (33%) patients. The median cervical tumor and nodal sizes were 5.3 cm (range: 2–10 cm) and 1.8 cm (range: 0.7–4.5 cm), respectively. The median number of positive nodes in each patient was 2 (range: 1–16), with the total number of positive nodes being 179, including all patients. All but one patient was treated with concurrent weekly cisplatin The dose to the pelvis and PA region was 45 Gy in 25 fractions, with a concomitant boost to involved nodes to a median dose of 55 Gy in 25 fractions (range: 54–59.4 Gy). The median brachytherapy dose was 27.5 Gy in 5 fractions using either intracavitary or interstitial technique. A follow-up PET-CT was performed at 12–16 weeks to assess response.

Results: Complete clinical and radiographic response at the first follow-up for all sites was seen in 47 (77%) patients. Persistent nodal disease or progression of nodal disease at the first follow-up was seen in two patients (pelvic nodal disease in one patient and another with a new PA node with lung metastases). At a mean follow-up of 29 months (range: 3–116 mo), eight additional patients developed recurrences. The median time to recurrence was 14 months (range: 10–36 mo). The sites of persistence or recurrent disease were the cervix (10, 16.3%), regional nodes (3, 4.9%), and distant (14, 23%) (some had more than one site of relapse). The 3-year risk of local, regional, and distant recurrence and disease-free survival (DFS) was 75.8%, 93.9%, 66.7%, and 56.9% respectively. The 3-year DFS for pelvic node only–versus pelvic plus PA node-positive disease was 63.8% versus 39%, respectively. On multivariate analysis, only stage predicted for worse DFS. The rate of late grade 3 and above complications was 4%.

Conclusions: Extended-field IMRT in patients with PET-positive pelvic nodes was well tolerated and resulted in very low regional recurrence rates. The dose of 55 Gy in 25 fractions was effective in eradicating disease in the involved nodes without increasing the risk of late complications. Distant metastases were the predominant mode of failure in these patients, and the OUTBACK trial may define the benefit of additional chemotherapy.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content